UNIVERSAL BIOSENSORS INC (UBI)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
UBI - UNIVERSAL BIOSENSORS INC
FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.18
Index:
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.205
07 Dec |
OPEN $0.21 |
HIGH $0.22 |
1,011,639 LOW $0.20 |
-0.015| OTHER COMPANIES IN THE SAME SECTOR | |||
| 4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . VHT . VTI . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -13.5 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 4.5 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 12.3 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -14.7 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -593.48 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -100.02 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -90.44 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -59.10 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -100.02 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -78.57 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -16.3 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 4 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 5 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 27 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 1.83 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 1.6 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 34.59 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 5 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 23 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 12 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
UBI STOCK CHART
FNArena News on UBI
Latest Medical Equipment & Devices News
| 1 |
Dr Boreham’s Crucible: Pro MedicusOct 23 2023 - Australia |
| 2 |
Dr Boreham’s Crucible: CyclopharmOct 09 2023 - Small Caps |
| 3 |
Dr Boreham’s Crucible: PainchekSep 11 2023 - Small Caps |
| 4 |
Margins Signal Integral Diagnostics RecoverySep 07 2023 - Australia |
| 5 |
ResMed: Finding A Base?Aug 15 2023 - Technicals |
| 6 |
August Turns ResMed Into Nigel NoMatesAug 09 2023 - Australia |
| 7 |
Dr Boreham’s Crucible: Lumos DiagnosticsJun 19 2023 - Small Caps |
| 8 |
Fisher & Paykel Healthcare: Lower Margin, Higher SpendingMay 30 2023 - Australia |
| 9 |
Dr Boreham’s Crucible: ImpedimedMay 08 2023 - Small Caps |
| 10 |
Treasure Chest: ResMed’s Benevolent MonopolyMay 01 2023 - Treasure Chest |
